Jump to:Page Content
The investors filed class actions against the drugmaker and others, alleging the defendants issued misstatements and failed to disclose material facts in violation of Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. The defendants settled for $12.8 million. Pub. Pension Fund Group v. KV Pharm. Co.